New cancer panel is promising in detecting viral mutations, cancer previously undetected -
Researchers at Sanford Health and Chronix Biomedical announced today the results a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral mutations and cancer must be reported in a poster presentation entitled "detection of new mutations of HPV and chromosomal imbalance number (CNI ) in oropharyngeal and laryngeal cancer using next generation sequencing (NGS) "(Abstract # 6072) at the American Society of Clinical Oncology annual Meeting (ASCO 2014), held from 30 May to 3 June, 2014 in Chicago. The panel identified the human papilloma virus (HPV) undetected by conventional laboratory tests and new undeclared HPV mutation sequences. It is estimated that each year there are about 30,000 cases of HPV-associated cancers in the United States.
next generation sequencing In the study, the researchers applied advanced (NGS) techniques to identify mutations associated with tumor in larynx and 10 patients with oropharyngeal cancer who underwent treatment standard chemoradiotherapy. As a control, two samples of respiratory papillamatous relapsing patients were analyzed. The single blind study looked at DNA biopsied patients who were positive or negative by the conventional HPV test. The new test identified sequences of HPV in 6 samples of conventional tests that identified 4. The new test agree with the conventional test in 5 other samples that were negative for HPV sequences. In addition, the new test identified mutations with HPV sequences previously unreported on HPV databases. In addition, the imbalance in the number of chromosomes found was consistent with oropharyngeal cancers.
a cancer patient analysis for genetic mutations is the basis to predict the results of treatment with various drugs and protocols cancer. At present, most cancer mutation panels are concentrated in less than 1 percent of the cancer genome with a limited predictive value. The preliminary conclusion of this study is the basis for a larger study planned designed to match these viral mutations and cancer in clinical results using a greatly expanded panel. Using a wider mutation panel, the accuracy of genetic tests should be increased significantly to predict optimal treatment decisions.
"These powerful new technologies allow us to better understand the role of viruses in cancer and the ability to make better patient by patient treatment decisions. In the next study, we plan to follow up using a liquid blood-based biopsy to determine in real time the effectiveness of treatment, "said Professor John H. Lee, MD, Department of research on cancer, Sanford Health and principal investigator the study.
"current technology uses limited amounts of data to make important treatment decisions. This new technology greatly increases the amount of critical medical data that we can use to increase the accuracy of treatment decisions. This new cancer panel has the potential to significantly improve patient care while significantly reducing the cost to the health system, "said the lead study author Howard B. Urnovitz, Ph.D., Chief Chronix biomedical management.
"This new comprehensive cancer genetics panel will make a significant contribution with a large benefit for cancer patients because the accurate prediction of treatment efficacy can guide treatment options that can be confirmed in weeks a liquid biopsy., "said Prof. Dr. Ekkehard Schütz, MD, Ph.D., head of biomedical Chronix technology.
About Sanford Health
EmoticonEmoticon